RT Journal
A1 Armstrong K
T1 CAn genomics bend the cost curve?
JF JAMA
JO JAMA
YR 2012
FD March 14
VO 307
IS 10
SP 1031
OP 1032
DO 10.1001/jama.2012.261
UL http://dx.doi.org/10.1001/jama.2012.261
AB 
Prior approaches to slowing the growth in US health care costs have had limited success. The use of cost-benefit analyses to make coverage or clinical decisions has proven socially and politically unacceptable in the United States. Managed care temporarily slowed cost increases in health care but the public backlash against restriction of choice undermined its potential long-term effects. Similarly, the unwillingness to include economic outcomes in the current investment in comparative effectiveness research will limit its effects on health care costs.1 New approaches are needed.